Magnus Ivarsson is currently head of discovery at Rodin Therapeutics, a Boston-based biopharmaceutical company focused on discovering and developing first-in-class therapeutics for synaptopathies. He has extensive expertise in using translational biomarkers to drive efficient and successful drug discovery and development. He most recently served as vice president and head of translational science at Proteostasis Therapeutics, a biopharmaceutical company dedicated to developing groundbreaking therapies for cystic fibrosis.
Previously, Magnus co-led the Translational Science Center for AstraZeneca in Sweden. He has also served as an associate research fellow at Pfizer and a team leader at Merck. He has been a key contributor to the advancement of multiple development candidates and IND/NDA submissions. Magnus is also an honorary associate professor in the department of optometry and vision science at the University of Melbourne, Australia. He has a Ph.D. in neurophysiology from Lund University, Sweden.